HTR2A and systemic sclerosis: Studies have suggested 5-HT2 receptors as potential targets of novel treatment options for several fibrotic conditions such as hepatic fibrosis, systemic scleroderma and pulmonary hypertension33, thus highlighting the wide potential of selective 5-HT2 receptor antagonists in treating fibrosis of different tissue origin.